Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 183 clinical trials
None
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability

This phase Ib/II trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with colorectal cancer (or with other solid tumors with microsatellite instability) that has spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as M7824, may …

adjuvant therapy
neutrophil count
adenocarcinoma of the colon
absolute neutrophil count
anti-pd-l1/tgfbetarii fusion protein m7824
  • 118 views
  • 03 Feb, 2021
  • 2 locations
None
NCT Neuro Master Match - N M (NOA-20)

The objective of NM is the improvement of overall survival of patients with glioblastoma with an unmethylated MGMT promoter based on molecular characterization and use of targeted compounds in a modern trial design. The progression-free survival rate at six months (PFS-6) will be used to make decisions.

  • 6 views
  • 24 Jan, 2021
  • 14 locations
None
Endoscopic Surveillance in Serrated Polyposis Syndrome and Low-risk of Advanced Neoplasia

The aim of the study is to determine if Serrated Poliposis Syndrome (SPS) patients with SPS criteria 2, with clearing phase achieved and without any advanced lesion or less than 5 relevant lesions at last colonoscopy have the same advanced neoplasia incidence in the surveillance colonoscopy at 2 or 3 …

bowel preparation
polypectomy
colonoscopy
cancer
chromoendoscopy
  • 0 views
  • 30 Sep, 2021
  • 1 location
None
BRAINFUL (BRAIN Tumor Focused Ultrasound-enabled Liquid Biopsy) Trial

Background Accessing brain tumor material for pathological diagnosis requires invasive procedures that carry risk to patients including brain hemorrhages and death. Liquid biopsies are emerging non-invasive alternatives to direct tumour biopsies but the abundance of circulating tumor DNA (ctDNA) is relatively low and this limits our ability to accurately make …

  • 0 views
  • 18 Jul, 2021
  • 1 location
None
HAI-Floxuridine or Liver-Tx Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Livermetasteses and Heavy Tumour Burden.

Patients with colorectal livermetasteses and heavy tumour burden and progression on 1st line chemotherapy have no other available treatment in Norway today other than 2nd line chemotherapy. The Investigators will randomize patients younger than 70 yrs old to HAI-floxuridine, or liver-Tx, in addition to 2nd line chemotherapy versus 2nd line …

  • 0 views
  • 15 Jul, 2021
  • 1 location
None
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma

It has been shown previously that gene expression profiling signature (a set of dysregulated genes) can be used for molecular classification, diagnosis, and prognosis of several types of cancers. In This study the hypothesise that resistant tumor may be due to genetic mutations and/or other alternative pathways that could be …

platelet count
international normalized ratio
cancer
vascular invasion
sorafenib
  • 16 views
  • 23 Jan, 2021
  • 1 location
None
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.

  • 16 views
  • 21 Jun, 2021
  • 8 locations
None
LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies

ROS1
EGFR
growth factor
BRAF
HER2
  • 19 views
  • 13 Oct, 2021
  • 12 locations
None
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

months for patients with BRAF wild-type tumours. After 1st line therapy, treatment outcomes with standard therapy are poor in patients with BRAF-mutated mCRC, with response rates (ORR) of 11%, a median

  • 0 views
  • 28 Jan, 2021
  • 12 locations
None
Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection

We explores the accuracy and sensitivity of rapid intraoperative detection of IDH, TERT, BRAF indicators through a prospective clinical multi-center study. This part includes a total of 300

BRAF
  • 0 views
  • 02 Jun, 2021
  • 4 locations